Annex 15 – Page 77 – Pharma Validation

Ophthalmic Ointment Manufacturing Vessel (Sigma/Planetary/Vacuum) – Qualification Execution Checklist

Qualification Execution Checklist Equipment: Ophthalmic Ointment Manufacturing Vessel (Sigma/Planetary/Vacuum) Subcategory: Ophthalmics (Sterile Eye Drops/Eye Ointments) Area: Production DQ/IQ/OQ/PQ Flags: Yes/Yes/Yes/Yes CSV Required: Yes Pre-start Checks Training completed SOPs approved User Requirements Specification (URS) approved Regulatory Affairs (RA) approved Calibration/PM Status…

Ophthalmic Ointment Manufacturing Vessel (Sigma/Planetary/Vacuum) – PQ Protocol

Document Control Number: PQ-EO-001 Version: 1.0 Effective Date: YYYY-MM-DD Review Date: YYYY-MM-DD Performance Qualification Protocol for Ophthalmic Ointment Manufacturing Vessel Tags: Equipment Validation, Ophthalmics, PQ Protocol, Performance Qualification Objective The objective of this Performance Qualification (PQ) protocol is to demonstrate…

Ophthalmic Ointment Manufacturing Vessel (Sigma/Planetary/Vacuum) – OQ Protocol

Document Control: Protocol Number: OQ-001 Version: 1.0 Effective Date: [Insert Date] Review Date: [Insert Date] Prepared By: [Insert Name] Approved By: [Insert Name] Operational Qualification Protocol for Ophthalmic Ointment Manufacturing Vessel Objective: To validate the operational performance of the Ophthalmic…

Ophthalmic Ointment Manufacturing Vessel (Sigma/Planetary/Vacuum) – IQ Protocol

Document Control: Version: 1.0 Date: 2023-10-01 Author: Validation Team Review Date: 2023-10-15 Installation Qualification Protocol for Ophthalmic Ointment Manufacturing Vessel Meta Description: This document outlines the Installation Qualification (IQ) protocol for the Ophthalmic Ointment Manufacturing Vessel, ensuring compliance with regulatory…

Ophthalmic Ointment Manufacturing Vessel (Sigma/Planetary/Vacuum) – DQ Protocol

Document Control: Document Number: DQ-001 Version: 1.0 Effective Date: [Insert Date] Review Date: [Insert Date] Design Qualification Protocol for Ophthalmic Ointment Manufacturing Vessel Objective: The objective of this Design Qualification (DQ) protocol is to ensure that the Ophthalmic Ointment Manufacturing…

Ophthalmic Ointment Manufacturing Vessel (Sigma/Planetary/Vacuum) – Equipment Validation SOP

Standard Operating Procedure for Validating Ophthalmic Ointment Manufacturing Equipment Equipment Validation, Ophthalmics, SOP, Sterile Eye Drops, Validation Purpose This SOP outlines the validation process for the Ophthalmic Ointment Manufacturing Vessel to ensure that the equipment meets regulatory and quality standards…

Lyophilizer (Freeze Dryer) – NDDS – Qualification Certificate Template

Qualification Certificate Equipment Information Equipment: Lyophilizer (Freeze Dryer) – NDDS Subcategory: NDDS – Liposomes & Lipid Nanoparticles (LNP) Area: Production Qualification Flags DQ: Yes IQ: Yes OQ: Yes PQ: Yes Qualification Details Equipment Identifier: [Equipment Identifier] Protocol References: [Protocol References]…

Lyophilizer (Freeze Dryer) – NDDS – Traceability Matrix (URS ↔ Tests)

URS ID URS Statement Risk (H/M/L) DQ Test Ref IQ Test Ref OQ Test Ref PQ Test Ref Evidence/Record Result URS-001 Verify shelf temperature control during lyophilization. H DQ-001 IQ-001 OQ-001 PQ-001 Temperature log files URS-002 Ensure vacuum pressure is…

Lyophilizer (Freeze Dryer) – NDDS – Validation Summary Report (VSR) Template

Validation Summary Report (VSR) Summary This Validation Summary Report (VSR) outlines the validation activities conducted for the Lyophilizer (Freeze Dryer) utilized in the production of NDDS, specifically for Liposomes and Lipid Nanoparticles (LNP). The report details the execution of the…

Lyophilizer (Freeze Dryer) – NDDS – Deviation Impact Assessment

Deviation Impact Assessment Template Equipment Details Equipment: Lyophilizer (Freeze Dryer) – NDDS Area: Production Criticality: Critical Product Impact: Direct CSV Required: Yes Deviation Details Description of Deviation: Classification Classification of Deviation: Major Minor Critical Product/Patient Impact Potential Impact on Product/Patient:…